About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.



  • SepAthenex announces positive recommendation by the DSMB and continues the Oraxol phase 3 program
  • Spectrum expands poziotinib clinical program to explore new areas including first-line treatment of NSCLC
  • AugMonterizine Capsule phase 3 clinical trial result featured in the Journal of Clinical Therapeutics
  • JulyReleases phase 3 clinical result of Rolontis in an oral presentation at the MASCC
  • Slated to market and sell Hugel’s Gugu-fill(Hyaluronic Acid Filler)
  • JunPresents three next-generation anti-cancer drugs at ASCO
  • Releases clinical results of Amosartan/Rovelito at ESH
  • Launches Monterizine Chewable Tab for children
  • MayWins FDA nod for arthritis treatment ‘Hyalrheuma’
  • Sanofi begins phase 3 trials of Hanmi’s diabetes drug candidate ‘efpeglenatide’
  • Apr Janssen starts phase 2 study on HM12525A, a biologic drug for the treatment of diabetes and obesity developed by Hanmi
  • Unveils three new anti-cancer drug candidates at AACR
  • Spectrum presents clinical trial results of poziotinib at AACR
  • Wins FDA approval of LAPSTriple Agonist phase 1 clinical trial
  • Oraxol gets orphan drug designation for angiosarcoma
  • JVM, an affliliate of Hanmi awarded for excellence in corporate disclosure
  • Spectrum publishes the trial results for poziotinib, a non-small-cell lung cancer treatment on Nature Medicine
  • Mar Hanmi Tams 0.4mg phase 3 clinical test results featured in the Journal of Clinical Therapeutics
  • Selected the short track speed skating gold medalist Kim Alang as its new model for Tenten, a chewable nutritional supplement
  • FebLAPSGlucagon Analog receives FDA Breakthrough Therapy Designation in congenital hyperinsulinemia
  • Spectrum presents ‘Rolontis’ met the Primary Endpoint in the Phase 3 ADVANCE study… sets to file BLA within 4Q
  • Sanofi sets to start two phase 3 clinical trials of efpeglenatide in 2018
  • Received industry first ‘BPW Gold Award’ for promoting gender equality
  • JanPromotes innovative drugs for NASH, rare diseases and targeted anti-cancer at JP Morgan event
  • Reports 916.6 billion won in revenue in 2017, operating profit soars 212.3%